117 related articles for article (PubMed ID: 8337897)
1. Urinary metabolites of pinacidil: I. Isolation and identification of the metabolites in rat urine.
Sakamoto K; Nakamura Y
Xenobiotica; 1993 Apr; 23(4):391-400. PubMed ID: 8337897
[TBL] [Abstract][Full Text] [Related]
2. Urinary metabolites of pinacidil. II. Species difference in the metabolism of pinacidil.
Sakamoto K; Nakamura Y
Xenobiotica; 1993 Jun; 23(6):649-56. PubMed ID: 8212738
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of the new antihypertensive agent pinacidil in rat, dog and man.
Eilertsen E; Magnussen MP; Petersen HJ; Rastrup-Andersen N; Sørensen H; Arrigoni-Martelli E
Xenobiotica; 1982 Mar; 12(3):187-96. PubMed ID: 7113255
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective disposition and metabolism of pinacidil in rat.
Sakamoto K; Nakamura Y
Xenobiotica; 1994 Apr; 24(4):329-38. PubMed ID: 8059536
[TBL] [Abstract][Full Text] [Related]
5. Effects of formulation on the pharmacokinetics of orally administered pinacidil in humans.
McBurney A; Farrow PR; Ward JW
J Pharm Sci; 1987 Dec; 76(12):940-1. PubMed ID: 3440941
[TBL] [Abstract][Full Text] [Related]
6. Disposition of [14C]pinacidil in humans.
DeLong AF; Oldham SW; DeSante KA; Nell G; Henry DP
J Pharm Sci; 1988 Feb; 77(2):153-6. PubMed ID: 3361430
[TBL] [Abstract][Full Text] [Related]
7. Pinacidil. Preclinical investigations.
Ahnfelt-Rønne I
Drugs; 1988; 36 Suppl 7():4-9. PubMed ID: 3076134
[TBL] [Abstract][Full Text] [Related]
8. Variable metabolism of pinacidil: lack of correlation with the debrisoquine and trimethylamine C- and N-oxidative polymorphisms.
Ayesh R; Al-Waiz M; McBurney A; Mitchell SC; Idle JR; Ward JW; Smith RL
Br J Clin Pharmacol; 1989 Apr; 27(4):423-8. PubMed ID: 2719898
[TBL] [Abstract][Full Text] [Related]
9. Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates.
Kitani M; Miyamoto G; Nagasawa M; Yamada T; Matsubara J; Uchida M; Odomi M
Drug Metab Dispos; 1997 Jun; 25(6):663-74. PubMed ID: 9193867
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following i.v. and oral administration in healthy volunteers.
McBurney A; Farrow PR; Ainsworth S; Ward JW
Br J Clin Pharmacol; 1985 Jan; 19(1):91-4. PubMed ID: 3978025
[TBL] [Abstract][Full Text] [Related]
11. [Effect of potassium channel openers on hypoxic pulmonary vasoconstriction].
Matsumoto H; Nakano H; Akiba Y; Osanai S; Tobise K; Onodera S
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1488-95. PubMed ID: 1434222
[TBL] [Abstract][Full Text] [Related]
12. Basal nitric oxide release differentially modulates vasodilations by pinacidil and levcromakalim in goat coronary artery.
Deka DK; Raviprakash V; Mishra SK
Eur J Pharmacol; 1998 May; 348(1):11-23. PubMed ID: 9650826
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of nitric oxide synthesis and ischemia/reperfusion attenuate coronary vasodilator response to pinacidil in isolated rat heart.
Maczewski M; Beresewicz A
J Physiol Pharmacol; 1997 Dec; 48(4):737-49. PubMed ID: 9444621
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.
Ward JW; McBurney A; Farrow PR; Sharp P
Eur J Clin Pharmacol; 1984; 26(5):603-8. PubMed ID: 6468476
[TBL] [Abstract][Full Text] [Related]
15. Identification and determination of phase I metabolites of propafenone in rat liver perfusate.
Tan W; Li Q; McKay G; Semple HA
J Pharm Biomed Anal; 1998 Feb; 16(6):991-1003. PubMed ID: 9547702
[TBL] [Abstract][Full Text] [Related]
16. Effect of a new vasodilator, pinacidil (P 1134), on potassium, noradrenaline and serotonin induced contractions in rabbit vascular tissues.
Nielsen CK; Arrigoni-Martelli E
Acta Pharmacol Toxicol (Copenh); 1981 Nov; 49(5):427-31. PubMed ID: 7345884
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of prazosin in rat, dog, and human liver microsomes and cryopreserved rat and human hepatocytes and characterization of metabolites by liquid chromatography/tandem mass spectrometry.
Erve JC; Vashishtha SC; DeMaio W; Talaat RE
Drug Metab Dispos; 2007 Jun; 35(6):908-16. PubMed ID: 17353349
[TBL] [Abstract][Full Text] [Related]
18. Dilating effect of perivascularly applied potassium channel openers cromakalim and pinacidil in rat and cat pial arteries in situ.
Wahl M; Parsons AA; Schilling L
Cardiovasc Res; 1994 Dec; 28(12):1803-7. PubMed ID: 7867033
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modeling between pinacidil or pinacidil-N-oxide plasma levels and systemic and regional hemodynamic effects in healthy volunteers.
Bellissant E; Chau NP; Thuillez C; Giudicelli JF
Fundam Clin Pharmacol; 1994; 8(5):437-45. PubMed ID: 7875638
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of the organic nitrate trans-N-(4-nitroxycyclohexyl)acetamide in dogs.
Zell C; Neidlein R; Strein K
Arzneimittelforschung; 1994 Sep; 44(9):1021-8. PubMed ID: 7986238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
